GlaxoSmithKline makes big down payment on biotech targeting 'synthetic viability' with startup ...

Retrieved on: 2020-12-18 14:26:15

Tags for this article:

Click the tags to see associated articles and topics

GlaxoSmithKline makes big down payment on biotech targeting 'synthetic viability' with startup .... View article details on hiswai:

Excerpt

Adrestia hopes to restore “<b>biological</b> balance” to dysfunctional or dying cells — a process coined “<b>synthetic</b> viability” —with its Disease Rebalancing ...

Article found on: endpts.com

View Original Article